Mereo BioPharma: Experts see price targets between 6 USD and 10 USD - Setrusumab could help with "brittle bone disease"

The Mereo BioPharma Group plc (ADRs) (MREO) is a biopharmaceutical company that has built a portfolio of six clinical product candidates, sourced from acquisitions of companies like Novartis and AstraZeneca. The pipeline particularly focuses on Setrusumab (UX-143) and Alvelestat (MPH966), which are being tested in various studies. Setrusumab is a monoclonal antibody in Phase 3 development for the treatment of Osteogenesis Imperfecta (OI), a rare genetic bone disorder. OI is also known as "brittle bone disease" because the bones of affected individuals...